A Study to Evaluate ALN-2232 in Participants With Obesity
ConditionObesity
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorAlnylam Pharmaceuticals
About this trial
The purpose of this study is to:
* evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
Eligibility criteria
Qualifiers
Has a body mass index (BMI) of ≥30 kg/m² and <40 kg/m²
Has a hemoglobin A1c (HbA1c) <6.5%
Disqualifiers
Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
Receiving therapies for chronic weight management or antidiabetic medications
Trial design
Treatments tested in this trial
- ALN-2232
- Placebo
- Tirzepatide
Treatment groups
156 Participants
are divided into 7 treatment groups7
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov